Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
Zacks
More News
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
Zacks
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Zacks
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Zacks
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -15.99% and -45.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.
Zacks
Immatics (IMTX) to Release Quarterly Earnings on Tuesday
Immatics (NASDAQ:IMTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-immatics-stock...
MarketBeat
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -14.82% and +2.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
>

Advertisement|Remove ads.